Sugi Predict

Sugi Predict / Compounds / SCHEMBL1680849

SCHEMBL1680849

SCHEMBL1680849

CCOC(=O)Cc1ccc(Br)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.45
▸ MAPT P10636 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ KMT2A Q03164 6/20 0.43
▸ MEN1 O00255 4/20 0.43
▸ TSHR P16473 2/20 0.43
▸ HTT P42858 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ S1PR4 O95977 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ S1PR1 P21453 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ JAK2 O60674 1/20 0.40
▸ PAK4 O96013 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ LCK P06239 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30336943 1.00 ALDH1A1 (0.45) ALDH1A1MAPTTP53KMT2AMEN1
SCHEMBL18524117 0.88 MAPT (0.43) ALDH1A1MAPTTP53KMT2AMEN1
SCHEMBL855301 0.87 ALDH1A1 (0.44) ALDH1A1MAPTTP53KMT2AMEN1
SCHEMBL31053271 0.84 KMT2A (0.47) ALDH1A1MAPTTP53KMT2AMEN1
SCHEMBL20772934 0.84 KMT2A (0.47) ALDH1A1MAPTTP53KMT2AMEN1
SCHEMBL707398 0.84 KMT2A (0.57) ALDH1A1MAPTTP53KMT2AMEN1
SCHEMBL31441299 0.84 KMT2A (0.57) ALDH1A1MAPTTP53KMT2AMEN1
SCHEMBL6024765 0.84 MAPT (0.44) ALDH1A1MAPTTP53KMT2AMEN1
SCHEMBL590168 0.84 HPGD (0.46) ALDH1A1MAPTKMT2AMEN1TSHR
SCHEMBL29536923 0.84 HPGD (0.46) ALDH1A1MAPTKMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 — — US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 — — US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 — — CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 — — CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 — — EP disclosed
CN-115836054-A IL4I1 inhibitors and methods of use 默沙东有限责任公司 2023-03-21 — — CN disclosed
US-20120270866-A1 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS INC. (US) 2012-10-25 — — US disclosed
US-20120270866-A1 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS INC. (US) 2012-10-25 — — US disclosed
CN-102648200-A 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders AFRAXIS INC 2012-08-22 — — CN disclosed
EP-2486037-A2 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS Afraxis, Inc. (US) 2012-08-15 — — EP disclosed
WO-2011159945-A2 METHODS FOR TREATING NEUROLOGICAL CONDITIONS AFRAXIS, INC. (US) 2011-12-22 — — WO disclosed
WO-2011159945-A2 METHODS FOR TREATING NEUROLOGICAL CONDITIONS AFRAXIS, INC. (US) 2011-12-22 — — WO disclosed
WO-2011044535-A2 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2011-04-14 — — WO disclosed
WO-2011044535-A2 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2011-04-14 — — WO disclosed
CN-100345850-C 3-phenyl-substituted pyridoindolones, their preparation and therapeutic use SANOFI AVENTIS (FR) 2007-10-31 — — CN disclosed
CN-1729190-A 3-phenyl-substituted pyridoindolones, their preparation and therapeutic use SANOFI AVENTIS (FR) 2006-02-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 ALDH1A1 653/4885MAPT 1152/4885TP53 4796/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 ALDH1A1 653/4885MAPT 1152/4885TP53 4796/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH ALDH1A1 3178/4885MAPT 4803/4885TP53 4826/4885
US-20120270866-A1 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK6, PAK5 ALDH1A1 2756/4885MAPT 232/4885TP53 3893/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 ALDH1A1 3094/4885MAPT 4737/4885TP53 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.